17:21 , Mar 2, 2018 |  BC Week In Review  |  Company News

MedImmune spins out autoimmune play Viela

The MedImmune LLC subsidiary of AstraZeneca plc (LSE:AZN; NYSE:AZN) is spinning out six compounds into severe autoimmune disease play Viela Bio Inc. (Gaithersburg, Md.). Bing Yao, who is head of MedImmune’s Respiratory, Inflammation & Autoimmunity...
07:40 , Feb 28, 2018 |  BC Extra  |  Company News

MedImmune spins out autoimmune play Viela

MedImmune LLC is spinning out six compounds into severe autoimmune disease play Viela Bio Inc. (Gaithersburg, Md.). Bing Yao, who is head of the AstraZeneca plc (LSE:AZN; NYSE:AZN) subsidiary’s Respiratory, Inflammation & Autoimmunity (RIA) Innovative...
08:00 , Nov 16, 2015 |  BC Week In Review  |  Clinical News

Anifrolumab: Phase II data

A double-blind, international Phase II trial in 305 patients with seropositive moderate to severe SLE showed that 300 mg IV anifrolumab every 4 weeks met the primary endpoint of a greater proportion of patients achieving...
08:00 , Nov 16, 2015 |  BioCentury  |  Product Development

On SLE's trail

AstraZeneca plc's MedImmune LLC unit is following a clinical development trail for lupus candidate anifrolumab first blazed by Benlysta belimumab. The company hopes that its track record of successful mid-stage trials in the indication have...
02:25 , Nov 11, 2015 |  BC Extra  |  Clinical News

AZ reports Phase II SLE data

The MedImmune LLC unit of AstraZeneca plc (LSE:AZN; NYSE:AZN) said the lower of two doses of anifrolumab ( MEDI-546) showed a statistically significant improvement on the primary endpoint in a Phase II trial to treat...
07:00 , May 19, 2014 |  BC Week In Review  |  Clinical News

Sifalimumab: Phase IIb data

AstraZeneca's MedImmune LLC unit reported top-line data from a double-blind, international Phase IIb trial in 431 patients with moderate to severe active SLE showing that 200, 600 and 1,200 mg doses of IV sifalimumab given...
07:00 , Apr 8, 2013 |  BioCentury  |  Strategy

AstraZeneca's reset

After spending at least $7 billion for late-stage assets in 2012, AstraZeneca plc believes it now has sufficient value in its Phase II/III pipeline to restore long-term growth. The attention of business development is now...
08:00 , Feb 22, 2010 |  BioCentury  |  Strategy

Roadmap to big cap

Rigel Pharmaceuticals Inc. is looking to last week's deal with AstraZeneca plc as the springboard from small cap biotech to fully functioning biopharmaceutical company. The deal provides Rigel with enough money to invest in its...
07:00 , Jul 27, 2009 |  BC Week In Review  |  Company News

Medarex, Bristol-Myers deal

Bristol-Myers plans to acquire Medarex in a tender offer of $16 per share, or about $2.4 billion in cash. Bristol-Myers said it expects Medarex to have $300 million in net cash at closing. The price...
07:00 , Jul 27, 2009 |  BioCentury  |  Strategy

Medarex pipeline

Medarex pipeline Therapeutics Product [Partner] Target Status [Lead indication] Ipilimumab (MDX-010) [Bristol-Myers Squibb Co. (NYSE:BMY)] CTLA-4 (CD152) receptor Ph III [melanoma] MDX-1100 Chemokine CXC motif ligand 10...